2seventy bio ( NASDAQ:TSVT – Get Free Report ) had its price objective cut by investment analysts at The Goldman Sachs Group from $27.00 to $24.00 in a report released on Tuesday, Benzinga reports. The firm currently has a 'buy' rating on the stock. The Goldman Sachs Group's price target indicates a potential upside of 277.36% from the stock's previous close. A number of other research firms also recently commented on TSVT. Morgan Stanley downgraded 2seventy bio from an 'overweight' rating to an 'equal weight' rating and cut their price objective for the stock from $25.

https://www.dailypolitical.com/2023/08/15/the-goldman-sachs-group-lowers-2seventy-bio-nasdaqtsvt-price-target-to-24-00.html

#dailypolitical